Full Press Release Details
Phoenix Tissue Repair Doses First Patient In Phase 1/2 Clinical Trial Of PTR-01 (BBP-589) For Treatment Of Recessive Dystrophic Epidermolysis Bullosa (RDEB).
BBIO
Phoenix Tissue Repair Doses First Patient In Phase 1/2 Clinical Trial Of PTR-01 (BBP-589) For Treatment Of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Key Takeaway: Phoenix Tissue Repair Doses First Patient In Phase 1/2 Clinical Trial Of PTR-01 (BBP-589) For Treatment Of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis